4D MOLECULAR THERAPEUTICS INC (FDMT) — insider trading
Health Care · NASDAQ
4D MOLECULAR THERAPEUTICS INC (FDMT) has 20 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 20 (latest 2026-07-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Kirn David | Director, Officer (See Remarks) | Open-market sale | 442 | $12.84 | $5.7K | Form 4 |
| 2026-07-10 | Kirn David | Director, Officer (See Remarks) | Open-market sale | 15,283 | $12.01 | $183.6K | Form 4 |
| 2026-07-09 | Kirn David | Director, Officer (See Remarks) | Open-market sale | 42,608 | $12.87 | $548.2K | Form 4 |
| 2026-06-30 | Bizily Scott | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,752 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Bizily Scott | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 814 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Bizily Scott | Officer (Chief Legal Officer) | Open-market sale | 6,566 | $14.00 | $91.9K | Form 4 |
| 2026-06-30 | Bizily Scott | Officer (Chief Legal Officer) | Option exercise / conversion | 5,752 | $6.49 | $37.3K | Form 4 |
| 2026-06-30 | Bizily Scott | Officer (Chief Legal Officer) | Option exercise / conversion | 814 | $4.14 | $3.4K | Form 4 |
| 2026-06-23 | Bizily Scott | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 9,810 | $0.00 | $0 | Form 4 |
| 2026-06-23 | Bizily Scott | Officer (Chief Legal Officer) | Open-market sale | 9,810 | $12.00 | $117.7K | Form 4 |
| 2026-06-23 | Bizily Scott | Officer (Chief Legal Officer) | Option exercise / conversion | 9,810 | $4.14 | $40.6K | Form 4 |
| 2026-06-22 | Kirn David | Director, Officer (See Remarks) | Open-market sale | 114,746 | $10.47 | $1.20M | Form 4 |
| 2026-06-17 | Chacko Jacob | Director | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | SBLENDORIO GLENN | Director | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | MILLIGAN JOHN F | Director | Grant / award / vesting (derivative) | 75,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | GRAY SUSANNAH | Director | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Miller-Rich Nancy | Director | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | THEUER CHARLES | Director | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Tomasello Shawn | Director | Grant / award / vesting (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Kirn David | Director, Officer (See Remarks) | Open-market sale | 1,922 | $10.02 | $19.3K | Form 4 |
Ask the chat about FDMT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: 4D MOLECULAR THERAPEUTICS INC (FDMT).
Last updated 2026-07-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.